Literature DB >> 22294424

Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case.

Takatoshi Nakamura1, Hiroyuki Mitomi, Wataru Onozato, Takeo Sato, Atsushi Ikeda, Masanori Naito, Naoto Ogura, Hiroki Kamata, Akira Ooki, Masahiko Watanabe.   

Abstract

This report describes the laparoscopic resection of a rectal GIST after treatment with imatinib mesylate. A 56-year-old male presented with a submucosal tumor (longest diameter, 8 cm) arising in the lower rectum. A core needle biopsy revealed that the tumor contained bundles of spindle-like cells. Immunostaining revealed that the tumor was positive for c-kit and CD34. Analysis of the c-kit gene revealed a substitution of ACA (threonine) by GCA (alanine) at codon 574 of exon 11. Imatinib mesylate (400 mg/day) was given as preoperative adjuvant therapy for 3 months, and the tumor shrank to 5 cm in diameter. Proctectomy with transanal anastomosis could be performed laparoscopically, while preserving the anus. There was no evidence of recurrence 2 years 6 months after surgery. Preoperative adjuvant chemotherapy with imatinib mesylate may permit the use of less invasive treatment procedures, allowing anal preservation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294424     DOI: 10.1007/s00595-012-0134-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.

Authors:  Hui Chen; Koji Isozaki; Kazuo Kinoshita; Akiko Ohashi; Yasuhisa Shinomura; Yuji Matsuzawa; Yukihiko Kitamura; Seiichi Hirota
Journal:  Int J Cancer       Date:  2003-05-20       Impact factor: 7.396

2.  Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.

Authors:  M Miettinen; M Furlong; M Sarlomo-Rikala; A Burke; L H Sobin; J Lasota
Journal:  Am J Surg Pathol       Date:  2001-09       Impact factor: 6.394

3.  Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.

Authors:  Shelly S Lo; Georgios I Papachristou; Sydney D Finkelstein; William P Conroy; Wolfgang H Schraut; Ramesh K Ramanathan
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

4.  Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.

Authors:  Takashi Akiyoshi; Masatoshi Oya; Yoshiya Fujimoto; Hiroya Kuroyanagi; Masashi Ueno; Toshiharu Yamaguchi; Shunji Takahashi; Kiyohiko Hatake; Masamichi Katori; Noriko Yamamoto; Tetsuichiro Muto
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

5.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

6.  Gastrointestinal stromal tumor of the rectum resected by laparoscopic surgery: report of a case.

Authors:  Takatoshi Nakamura; Atsushi Ihara; Hiroyuki Mitomi; Yukihito Kokuba; Takeo Sato; Heita Ozawa; Kazuhiko Hatade; Wataru Onozato; Masahiko Watanabe
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

7.  Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case.

Authors:  Yuma Ebihara; Shunichi Okushiba; You Kawarada; Shuji Kitashiro; Hiroyuki Katoh; Satoshi Kondo
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

8.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authors:  Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Journal:  J Surg Oncol       Date:  2009-01-01       Impact factor: 3.454

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more
  6 in total

1.  Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum.

Authors:  Yoshiya Fujimoto; Takashi Akiyoshi; Tsuyoshi Konishi; Satoshi Nagayama; Yosuke Fukunaga; Masashi Ueno
Journal:  Int J Colorectal Dis       Date:  2013-09-10       Impact factor: 2.571

Review 2.  Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.

Authors:  Manabu Kaneko; Shigenobu Emoto; Koji Murono; Hirofumi Sonoda; Masaya Hiyoshi; Kazuhito Sasaki; Yasutaka Shuno; Takeshi Nishikawa; Toshiaki Tanaka; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa
Journal:  Surg Today       Date:  2018-11-15       Impact factor: 2.549

3.  Needle tract seeding and abdominal recurrence following pre-treatment biopsy of gastrointestinal stromal tumors (GIST): results of a systematic review.

Authors:  Jens Jakob; Rashad Salameh; David Wichmann; Nicos Charalambous; Anne-Christine Zygmunt; Inga Kreisel; Judith Heinz; Michael Ghadimi; Ulrich Ronellenfitsch
Journal:  BMC Surg       Date:  2022-05-21       Impact factor: 2.030

4.  Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy.

Authors:  Hiroaki Nozawa; Takamitsu Kanazawa; Toshiaki Tanaka; Masao Takahashi; Soichiro Ishihara; Eiji Sunami; Joji Kitayama; Masako Ikemura; Issei Komuro; Toshiaki Watanabe
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

5.  Transanal minimally invasive surgery (TAMIS) approach for large juxta-anal gastrointestinal stromal tumour.

Authors:  Nicolas Wachter; Marcus-Alexander Wörns; Daniel Pinto Dos Santos; Hauke Lang; Tobias Huber; Werner Kneist
Journal:  J Minim Access Surg       Date:  2016 Jul-Sep       Impact factor: 1.407

Review 6.  Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib.

Authors:  Hui Qu; ZhaoHui Xu; YanYing Ren; ZeZhong Gong; Ri Hyok Ju; Fan Zhang; HaoNan Kang; Yang Xu; Xin Chen
Journal:  Cancer Manag Res       Date:  2022-03-16       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.